Physician profile
Jerry P Abraham
NPI 1932514874
$8,514.39
in general payments reported to CMS, 2019-2025
14 companies · $7,353 in 2025
The $7,353 reported for 2025 was more than what 99% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $116 · 2021: $57.92 · 2022: $58.62 · 2023: $395 · 2024: $533 · 2025: $7,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,500 · Travel and Lodging: $1,954 · Food and Beverage: $1,795 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,500.00 |
| Travel and Lodging | $1,954.19 |
| Food and Beverage | $1,794.90 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $7,213.25 | 2025 | Caplyta |
| Viiv Healthcare Company | $396.09 | 2023-2024 | Apretude, Dovato, Cabenuva |
| Pfizer INC. | $300.00 | 2024 | |
| Janssen Pharmaceuticals, INC | $152.03 | 2021-2023 | Invega Sustenna |
| Indivior INC. | $93.35 | 2020 | |
| Abbott Laboratories | $75.57 | 2023-2025 | Esprit, Supera, Perclose Proglide |
| Novo Nordisk INC | $57.40 | 2025 | Wegovy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $53.79 | 2024 | Rexulti |
| Hologic Sales and Service, LLC | $42.66 | 2021-2022 | |
| Abbvie INC. | $34.97 | 2022 | |
| Merck Sharp & Dohme LLC | $31.07 | 2025 | Capvaxive, M-M-R II, Gardasil 9 |
| Bausch Health US, LLC | $23.14 | 2020 | |
| Lilly USA, LLC | $20.96 | 2025 | Zepbound, Mounjaro |
| Neurocrine Biosciences, INC. | $20.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.